1. Positive effect: Studies in recent years have confirmed that alpha-glucosidase inhibitors in acarbose were found to reduce cardiovascular events in patients with low glucose tolerance, but the effect on cardiovascular complications of type 2 diabetes also needs further confirmation. For those with predominantly elevated postprandial glucose, metformin and α-glucosidase inhibitors are preferred; the reduction of HbA1c by α-glucosidase inhibitors is small, 0.5% to 0.8%. However, there is some benefit for cardiovascular disease. Second, DPP-4 inhibitors, such as saxagliptin, lower glucose by increasing endogenous GLP-1 concentration, with weaker efficacy than insulinotropic agents. On the one hand, DPP-4 inhibitors can lower glucose, rarely cause hypoglycemia, but also elevate endogenous GLP-1, and GLP-1 can improve the endothelial function of blood vessels in type 2 diabetic patients, improve heart function in diabetic patients with heart failure, indirectly allowing cardiovascular benefits, at the same time, has the ability to regulate the endothelial progenitor cells in the circulation, repairing vascular endothelial cells, directly allowing cardiovascular benefits. 2, side effects: thiazolidinediones, such as we say rosiglitazone, pioglitazone, etc., will reduce HbA1c 1% to 1.5%, but may have increased weight, while increasing the risk of heart failure. Therefore, thiazolidinediones should be disabled in patients with heart failure. The application of glucose-lowering drugs must pay attention to the monitoring of cardiac function and to the positive side effects of the drugs.